September 9, 2022 5:44pm
Pre-open indications: 1 HIT, 1 MISS and 1 Pump/Promote
The Biostage (BSTG) Chronicles: who is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; is he the the ultimate funder of DST Capital or is it his wife Mrs bin Zhou, of Weston, Mass? Should the SEC, FBI and CIA be reviewing his Beijing, China communist penetration of the U.S. bioscience industry utilizing BSTG?
Biostage is at it <the pump/promote of share price and volume< again: “Biostage (BSTG +$0.06 (was +$0.26) with 3,619 shares tradedafter mutiple dowwn of flat sessions?
WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions.
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +377.19 points (+1.19) the S&P closed UP +61.18 points (+1.53%) while the Nasdaq closed UP +250.18 points (+2.11%)
U.S. stocks rose Friday following a choppy trading session; extended a broad-based rebound Friday, with Wall Street on pace to snap a three-week losing streak.
Stocks have been volatile recently as expectations of a 0.75 percentage point rate hike this month grew on Wall Street, after the Fed chair said again that he is “strongly committed” to bringing down inflation. <CNBC>
All three (3) indexes snapped a three (3) week losing streak with the Dow adding +2.66% on the week, the S&P 500 +3.65% while the Nasdaq gained +4.14%.
Economic Data Docket: Investor sentiment dropped again this week, with just 18.1% of respondents telling AAII they are bullish in the latest survey, down from 21.9% last week. Meanwhile, 53.3% of investors said they were bearish, up from 50.4% in the previous week.
RegMed Investor’s (RMi) Pre-Open: “share pricing run Issues = volatility and resistance, although stock futures point to gains.” … https://www.regmedinvestors.com/articles/12596
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Friday’s advance/decline line opened positive at 27 up/ 6 down and 2 flats, stayed positive with 22 up/13 down and 0 flat at the mid-day, ending with a positive close of 21/14 and 0 flat.
- Thursday’s advance/decline line opened positive at 29 up/ 3 down and 3 flats, stayed positive with 32 up/3 down and 0 flat at the mid-day, ending with a positive close of 30/5 and 0 flat.
- Wednesday’s advance/decline line opened positive at 26 up/ 7 down and 2 flats, stayed positive with 27 up/8 down at the mid-day, ending with a positive close of 28/6 and 1 flat.
- Tuesday’s advance/decline line opened negative at 9 up/ 22 down and 4 flats, stayed negative with 7 up/26 and 2 flats down at the mid-day, ending with a negative close of 8/25 and 2 flats.
- Monday was a holiday
Pre-open Indications: 1 HIT <Beam therapeutics (BEAM +$0.44)> 1 MISS <uniQure (QURE -$0.40)> 1 Pump/Promote <Biostage (BSTG +$0.06 (was +$0.26) with 3,619 shares traded)>
- Friday - Sector volume was LOW with 5 of the 21-upside having higher than the 3-month average volume with LOW volume of 1 of 14-downside having higher than the 3-month average volume
- Thursday - Sector volume was LOW with 7 of the 30-upside having higher than the 3-month average volume with LOW volume of 0 of 5-downside having higher than the 3-month average volume
- Wednesday - Sector volume was LOW with 4 of the 28-upside having higher than the 3-month average volume with LOW volume of 1 of 6-downside having higher than the 3-month average volume
- Tuesday - Sector volume was LOW with 2 of the 8-upside having higher than the 3-month average volume with LOW volume of 3 of 25-downside having higher than the 3-month average volume
- Monday – was a holiday
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Friday, the IBB was up +1.12% and the XBI was up +0.67%
- Thursday, the IBB was up +3.33% and the XBI was up +3.10%
- Wednesday, the IBB was up +2.80% and the XBI was up +4.24%
- Tuesday, the IBB was down -1.36% and the XBI was down -2.85%
- Monday was a holiday
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Friday was down -0.82 points or -3.47% at 22.79
- Thursday was down -1.02 points or -4.14% at 23.62
- Wednesday was down -2.16 points or -8.03% at 24.75
- Tuesday was up +0.92 points or +3.54% at 26.91
- Monday was a holiday
Jumping with share pricing momentum (10 of 21):
- Intellia Therapeutics (NTLA +$3.72 after Thursday’s +$3.72, Wednesday’s +$2.24 and Tuesday’s -$0.64),
- Ionis Pharmaceuticals (IONS +$2.57 after Thursday’s +$0.82, Wednesday’s +$1.80),
- Ultragenyx (RARE +$1.51),
- AxoGen (AXGN +$1.27),
- Sage Therapeutics (SAGE +$0.82 after Thursday’s +$2.14, Wednesday’s +$1.53 and Tuesday’s -$1.14),
- Vericel (VCEL +$0.77 after Thursday’s +$0.73 and Wednesday’s +$1.90),
- CRISPR Therapeutics (CRSP +$0.69 after Thursday’s +$1.26, Wednesday’s +$2.25 and Tuesday’s -$0.98),
- Regenxbio (RGNX +$0.61),
- Beam Therapeutics (BEAM +$0.44 after Thursday’s +$1.26, Wednesday’s +$2.88 and Tuesday’s +$0.25),
- Brainstorm Cell Therapeutics (BCLI +$0.41),
Closing down (14 of 14):
- Editas Medicine (EDIT -$0.37),
- UniQure NV (QURE -$0.40),
- Caribou Biosciences (CRBU -$0.42),
- Verve Therapeutics (VERV -$1.11 after Thursday’s -$0.08 and Wednesday’s +$3.60),
- Alnylam Pharmaceuticals (ALNY -$3.03 after Thursday’s +$17.44, Wednesday’s +$7.60 and Tuesday’s -$4.19),
- Global Blood Therapeutics (GBT -$0.22 after Thursday’s -$0.01),
- Voyager Therapeutics (VYGR-$0.20),
- Fate Therapeutics (FATE -$0.16 after Thursday’s +$0.95, Wednesday’s +$2.01 and Tuesday’s -$1.42),
- Verastem (VSTM -$0.09),
- BioLife Solutions (BLFS -$0.08 after Thursday’s +$1.34),
- Cellectis SA (CLLS -$0.07),
- Sangamo Therapeutics (SGMO -$0.07),
- Homology Medicine (FIXX -$0.03),
- MiMedx (MDXG -$0.03),
- Friday closed positive with 21 incliner, 14 decliners and 0 flat
- Thursday closed positive with 30 incliner, 5 decliners and 0 flat
- Wednesday closed positive with 28 incliner, 6 decliners and 1 flat
- Tuesday closed negative with 8 incliner, 25 decliners and 2 flats
- Monday was a holiday
The BOTTOM LINE: I try to keep it simple … and short!
September started with 1 holiday, 4 positive and 2 negative closes; August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.
As I continually question, “The real question that should be asked is how many companies are at the end of sentiments … leash? Start by looking at cell and gene therapy companies trading below cash!”
I find it very interesting to evaluate share price over earnings and a shortage of revenue reporting as a proxy for share pricing performance?
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.